SMi Group's 19th annual Pharmaceutical Pricing & Reimbursement conference is SMi Group's longest running conference. The Early Bird expires this Friday

1. PLUS AN INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 23rd October 2013, Holiday Inn Regents Park, London, UK
HTA Uncovered
Workshop Leaders:
Janice Haigh, Practice Leader, Market Access, Europe, Quintiles & Anke van Engen, Director Consulting, Quintiles
8.30am - 12.30pm
2013Holiday Inn Regents Park | LONDON, UK
Pharmaceutical Pricing
& Reimbursement
21st & 22nd
OCTOBER
• Patrick Mollon, Director Global HE&OR Critical Care,
Novartis
• Anne-Toni Rodgers, Global Pricing and Market Access,
AstraZeneca
• Peter Hertzman, Director, Bristol Myers Squibb
• Martin Brown, Director, Novartis
• Franz Pichler, Director, Global Public Policy, Eli Lilly & Co
• Sarah Pitiluck, Senior Director, Global Pricing &
Reimbursement, Alexion Pharma
• Janice Haigh, Director Market Access, Quintiles
• Leslie Galloway, Chairman, Ethical Medicines Industry
Group
• Kirsten Bröckers, Senior Legal Advisor, Celgene
CONFERENCE SPEAKERS INCLUDEWHY ATTEND THIS EVENT
• Understand how value based pricing will affect
the U.Ks pricing market and what to expect
• Discuss key market access strategies with a
range of case studies including those currently
being developed successfully with orphan drugs
• Evaluate current strategies with the new NICE
network reforms
• See the establishment of the pan-European HTA
network and its current effects
• Develop future cross sector market access
strategies
SMi Presents their 19th annual
www.pharmaceuticalpricing.co.uk
BOOK BY 28TH JUNE AND SAVE £300 I BOOK BY 19TH JULY AND SAVE £100
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
BO
O
K
BY
JUN
E
28TH
A
N
D
SA
VE
£300
BO
O
K
BY
JULY
19th
A
N
D
SA
VE
£100
“2012 was a great demonstration of current events,
2013 is set for more of the same.”

2. Pharmaceutical Pricing & Reimbursement 2013
Day One 21st October 2013
Register online at www.pharmaceuticalpricing.co.uk• Alternatively f
www.pharmaceu
Supported by
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
Donald Macarthur, Global Pharmaceutical Business Analyst,
JustPharmaReports
VALUE BASED PRICING & FUTURE EFFECTS
9.10 Getting ready for value-based pricing: What can we do
to prepare?
• Planning for value based pricing in product development
• Considering a broader definition of value
• Developing an understanding of the new pricing process
Martin Brown, Head of Health Economics and Outcomes
Research, Novartis
9.50 Value Based Pricing
• Implications for PPRS
• What is outside the negotiations?
• How will value be measured?
Leslie Galloway, Chairman, Ethical Medicines Industry Group
10.30 Morning Coffee
HTA & VALUE DELIVERY
11.00 Establishment of the permanent pan-European HTA network:
implications for HTA and coverage decision making
• Timeline and process to the establishment of the network
• The role of EUnetHTA in terms of operational implementing
• Key activities proposed for the network and implications of
these activities for pharma
Franz Pichler, Director, Global Public Policy, Eli Lilly & Co
11.40 The challenge of value delivery
• How do global value messages translate in the local
environment?
• What types of value messages best support local
negotiations?
• How do we make sure that the reimbursement price
agreed at national level becomes the realised price at
local level?
Janice Haigh, Practice Leader, Market Access, Europe,
Quintiles
12.20 Networking Lunch
1.50 Integration of Health-Economics and Market Access in the
development of innovative drugs
• Value-Based Development: need and opportunities to
demonstrate value
• Health-Economic strategies to anticipate Market Access
needs
• Methods and Tools supporting value evidence generation
Patrick Mollon, Director Global HE&OR Critical Care, Novartis
2.30 New Evidence on the Effectiveness Gap; How Pharma can
deliver
• The current problem: case studies in COPD and cancer
• International comparisons of the effectiveness gap—
France,UK,Germany and Finland
• Partnership with pharma and health services to deliver
therapeutic results
Nick Basanquet, Professor of Health Policy, Imperial College
London
3.10 Afternoon Tea
3.40 No-one benefits from flying with empty planes: What options
do we have to improve access in oncology? Experiences
from Scandinavia
• Patients are benefiting from many new and exciting
innovative oncology products. However, the discrepancies
between providers’ and payers’ expectations have still to
be resolved.
• There are various contractual options tested out in reality in
order to resolve the discrepancies. What are the pros and
cons with these options
• Examples of the above from the Scandinavian markets
Peter Hertzman, Nordic Market Access Director,
Bristol Myers Squibb
4.20 Implications of requiring traditional health economic
assessments when evaluating ultra-orphan drugs
• Traditional cost-effectiveness analyses are not an
appropriate method to evaluate ultra-orphan drugs and
can have a negative impact on patient access to
treatments
• Countries that require traditional economic analyses
inappropriately disadvantage patients with ultra-rare
diseases
• Instead, review agencies should look at a combination of
other factors when evaluating such drugs
Sarah Pitluck, Senior Director, Global Pricing &
Reimbursement, Alexion Pharmaceuticals Inc
5.00 Chairman's Closing Remarks and Close of Day One
SPONSORSHIP OPPORTUNITIES
Our pharmaceutical events are research-based and content-driven with regular contact with major industry personnel and cover a
wide range of industry sectors. For more information, please contact Alia Malick on +44 (0) 207 827 6168
or email amalick@smi-online.co.uk

3. fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
uticalpricing.co.uk
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
Donald Macathur, Global Pharmaceutical Business Analyst,
JustPharmaReports
U.K. MARKET ACCESS & NICE REFORMS
9.10 The new NICE and its global network
• A new Leadership … a New NICE?
• A UK Government Export - understand how NICE
proactively shapes the Pricing & Reimbursement
environment internationally
• Plan your global response
Anne-Toni Rodgers, Global Payer Lead, AstraZeneca
9.50 UK Market Access-post-change challenges
• Specialised commissioning
• Health informatics
• Joint working
• Case study
Richard Lomas, National Commissioning Manager MS,
Genzyme
10.30 Morning Coffee
11.00 Key learnings of 2 years of AMNOG
• Pricing and additional benefit
• Do innovative drugs still have a chance?
• Roadblocks moving forward
• Case study
Bertram Häussler, Director, IGES Institut
11.40 Healthcare reforms in Europe — How are they effecting P&R
• A revisited welfare state: between cost containment and
equal access
• Forward enlarged private HC expenditure
• Devoluting locally HC and pharma management
• Narrow price corridors, parallel trade and economic
differentials among EU Countries
• New models and schemes of P&R to face both cost
containment and equal access
• Different formularies management nationally and locally
Fabrizio Gianfrate, Professor of Health Economics, University
of Ferrara
12.20 Networking Lunch
HEALTHCARE REFORMS & EU TRANSPARENCY
1.50 Pricing of pharmaceuticals in a resource constrained
environment
• Healthcare policies in a period of recession
• Policies relating to pharmaceuticals during recessionary
periods
• New initiatives in pharmaceutical pricing
• The role of HTA
Ceri Phillips, Professor of Health Economics and Head of the
Institute for Health Research, Swansea University
2.30 Session reserved for Celgene
Kirsten Bröckers, Senior Legal Advisor, Celgene
3.10 Afternoon Tea
3.40 Japan: The Land that Cost Containment Forgot
• Pricing environment in Japan vs leading western countries
• Price comparisons
• Market entry strategies
• Prospects for change
Donald Macarthur, Global Pharmaceutical Business Analyst,
JustPharmaReports
4.20 Reform of the EU transparency directive
• The push for reform – issues not covered in the 1989
Directive
• The content and status of the reform proposal
• Next steps – when the changes will take effect in practice
James Killick, Partner, White & Case L L P
5.00 Chairman's Closing Remarks and Close of Day Two
Supported by
Want to know how you can get involved? Interested in promoting your pharmaceutical services to this market?
Contact Margaret Mugema,
SMi Marketing on +44 (0)20 7827 6072 or email mmugema@smi-online.co.uk
Day Two Tuesday 22nd October 2013

4. Overview of workshop
Understand the HTA World globally. Quintiles tracks
100 agencies around the world to monitor and
understand their decision making processes. The
main part of the workshop will provide a factual
understanding of the HTA map – who are the key
agencies, from what perspective is their evaluation,
what types of evidence do they require, what
typically drives HTA success or failure?
The final part of the workshop will reveal some
secrets about the main HTA bodies – what are the
rules which are not published, which agencies are
the most influential, what you can’t learn from
interviews or ad-boards.
Note: attendees from pharma companies only.
Programme:
8.30 Registration & Coffee
9.00 Understanding the HTA map
• Key agencies
• Types of assessment and evaluation
• Differences and similarities
11.00 Break for Coffee
11.30 HTA uncovered
• Drivers of success and failure
• What they dont print in the rules
12.00 Q&A
12.30 Close of workshop
About the workshop hosts:
Janice Haigh Practice Leader, Market Access,
Quintiles
Janice joined Quintiles Consulting in January 2012
as Practice Leader for Market Access in Europe.
From 2006 to December 2011, Janice was the
Senior Director Pricing and Market Access for
Astellas Pharma, Europe and was responsible for
development and implementation of pricing and
market access strategy for new and in market
products, working closely with brand teams and
affiliates price management, analysing the effect
of price changes on other markets. Janice also
designed, implemented and managed Astellas’s
supply chain integrity program which ensured the
matching of supply and demand of products in
Europe. Before joining Astellas in 2006, Janice
worked in consultancy for 20 years, including
almost 10 years at IMS Health/Cambridge Pharma
Consultancy where she was responsible for leading
projects involving pricing, parallel trade, health
economics and health policy. Clients included
European and global pharmaceutical companies
but also trade associations and government
bodies such as the European Commission.
HTA Uncovered
HALF-DAY POST-CONFERENCE AM WORKSHOP
23rd October 2013,
Holiday Inn Regents Park, London
8.30am - 12.30pm
In association with
Janice Haigh, Practice Leader, Market Access, Europe,
Quintiles &
Anke van Engen, Director Consulting, Quintiles

5. SMi PHARMACEUTICALS
FORWARD PLANNER 2013
JUNE
RNAi & Nanotechnology
5 - 6 June 2013, London
Biobanking
24 - 25 June 2013, London
JULY
Pharmacovigilance
1 - 2 July 2013, London
Cell Culture
3 - 4 July 2013, London
SEPTEMBER
Cancer Vaccines
18 - 19 September 2013, London
OCTOBER
Biosimilars & Biobetters
1 - 2 October 2013, London
Diabetes
1 - 2 October 2013, London
Orphan Drugs
14 - 15 October 2013, London
COPD: Novel Therapeutics and
Management Strategies
16 - 17 October 2013, London
European Pharmaceutical
Pricing & Reimbursement
21 - 22 October 2013, London
Point of Care Diagnostics
- Market Opportunities and
Technology Trents
23 - 24 October 2013, London
NOVEMBER
Cell Based Assays
18 - 19 November 2013, London
Clinical Trials in CNS
18 - 19 November 2013, London
DECEMBER
Cold Chain Distribution
3 - 4 December 2013, London

6. PHARMACEUTICAL PRICING & REIMBURSEMENT
Conference: 21 & 22 October | Holiday Inn Regents Park | LONDON, UK Workshops: 23rd October 2013, London
4 WAYS TO REGISTER
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
www.pharmaceuticalpricing.co.uk
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk
□ Book by 28th June to receive £300 off the conference price
□ Book by 19th July to receive £100 off the conference price
EARLY BIRD
DISCOUNT
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-085 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment
are below. Please indicate method of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
CONFERENCE PRICES
DOCUMENTATION (Shipped 10-14 days after the
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & 2 Workshops £2697.00 + VAT £3236.40
□ Conference & 1 Workshop £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ 1 Workshop only £599.00 + VAT £718.80
□ 2 Workshops only £1198.00 + VAT £1437.60
Workshop A □ Workshop B □
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
GROUP DISCOUNTS AVAILABLE
The Conference fee includes refreshments, lunch, conference papers and
CD ROM containing all of the presentations.
I cannot attend but would like to purchase access to the following Document
Portal/paper copy documentation: Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations - paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on CD ROMs and Literature Distribution for all UK customers and for those EU
customers not supplying a registration number for their own country here:
_______________________
PAYMENT
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders
placed for Documentation or the Document Portal as these are reproduced specifically to order.
If we have to cancel the event for any reason, then we will make a full refund immediately, but
disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about
other products and services. Unless you tick here □ we may also share your data with third parties
offering complementary products or services. If you have any queries or want to update any of
the data that we hold then please contact our Database Manager databasemanager@smi-
online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above
your address on the attached letter.
Unique Reference Number
Our Reference P-085
Terms and Conditions of Booking
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
VENUE Holiday Inn Regents Park, Carburton Street, London W1W 5EE
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712